← FDA DRUG APPROVALS

FDA ANDA · ANDA091427

PAROXETINE HYDROCHLORIDE

Sponsor: AUROBINDO PHARMA USA

APPLICATION
ANDA091427
TYPE
ANDA
ORIGINAL APPROVAL
2011-04-14
LATEST ACTION
2026-04-06
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

PAROXETINE HYDROCHLORIDEPrescription
PAROXETINE HYDROCHLORIDE EQ 37.5MG BASE · TABLET, EXTENDED RELEASE · ORAL

Approval history

2026-04-06Labeling · Supplement 14 · standardAP
2026-04-06Labeling · Supplement 15 · standardAP
2021-05-04Labeling · Supplement 9 · standardAP
2021-05-04Labeling · Supplement 11 · standardAP
2015-07-15Labeling · Supplement 6 · standardAP
2013-12-27Labeling · Supplement 5 · standardAP
2011-12-27Labeling · Supplement 2AP
2011-06-24Labeling · Supplement 1AP
2011-04-14OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →